Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments GlobeNewswire - Fri Nov 8, 7:00AM CST

MNPR : 18.45 (+1.99%)
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock GlobeNewswire - Wed Oct 30, 12:42PM CDT

MNPR : 18.45 (+1.99%)
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock GlobeNewswire - Mon Oct 28, 8:15PM CDT

MNPR : 18.45 (+1.99%)
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire - Mon Oct 28, 3:00PM CDT

MNPR : 18.45 (+1.99%)
MarketBeat Week in Review – 10/21- 10/25 MarketBeat - Sat Oct 26, 6:00AM CDT

Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatility

NVDA : 140.15 (-1.29%)
META : 554.40 (+0.06%)
GTLB : 59.96 (+0.15%)
MNPR : 18.45 (+1.99%)
RKLB : 19.29 (+1.53%)
GS : 587.99 (-0.94%)
SERV : 8.03 (+0.37%)
TSLA : 338.74 (+5.62%)
TLN : 207.49 (+3.52%)
AMD : 138.93 (+2.99%)
SOFI : 13.93 (+2.20%)
UBER : 69.33 (-5.35%)
Author
Monopar Therapeutics Skyrockets 400% on Licensing Deal MarketBeat - Fri Oct 25, 7:12AM CDT

Monopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.

MNPR : 18.45 (+1.99%)
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate GlobeNewswire - Thu Oct 24, 6:00AM CDT

MNPR : 18.45 (+1.99%)
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 GlobeNewswire - Tue Oct 22, 7:00AM CDT

MNPR : 18.45 (+1.99%)
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers GlobeNewswire - Tue Oct 15, 7:00AM CDT

MNPR : 18.45 (+1.99%)
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers GlobeNewswire - Mon Oct 7, 7:00AM CDT

MNPR : 18.45 (+1.99%)

Barchart Exclusives

Supercharge Your Dividends with this Options Strategy Barchart - 22 minutes ago
Omega Healthcare Investors (OHI) is a healthcare REIT that pays a dividend of 6.69%. Using options we can supercharge the yield on our OHI shares by using a covered call strategy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot